Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC312 in relapsed/refractory CD19+ B-cell malignancies
NCT06037018Phase 1Recruiting
- Sponsor
- CytoCares
- Start
- Aug 2023
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CC312 in non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL), sponsored by CytoCares. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events. Started Aug 2023; status: recruiting.
02
Drugs
CC312
03
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT06037018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06037018.